All News

Aficamten improved exercise capacity across submaximal, peak, and recovery measures.

These phase 3 studies are evaluating outcomes among patients living with polycythemia vera, myelofibrosis, and essential thrombocythemia.

Texas abortion ban worsens maternal mental health; SCD trials exclude 90% of adults; nutrition, hepatitis B, and cost-control gaps persist.

A new study finds Texas's abortion ban raised the likelihood of poor maternal mental health by 2.5 points—and 7 points for mothers on Medicaid.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

EHA 2026 highlights included practice-changing immunotherapy data in relapsed/refractory multiple myeloma and high-risk pediatric B-cell ALL, plus insights on childhood cancer predisposition.

Experts at ADA 2026 say nutrition guidelines must be personalized, culturally responsive, and built on research that reflects the patients they're meant to serve.

Robert Andrews, CEO, Healthcare Transformation Alliance, provides insight on what workers' compensation tells us about managing health care costs.

David Brueggeman, MBA, breaks down the underpriced financial risks, redetermination lessons, and what accountable AI actually requires from health plans.

Spanish dermatology consensus guides alopecia areata treatment escalation, highlighting JAK inhibitors, SALT-based staging, special-population care, and essential screening requirements.

The FDA approved the first oral carbapenem, tebipenem pivoxil, for complicated UTIs, offering an alternative to intravenous therapy.

Mobile health models that include artificial intelligence and smartphone imaging can help address gaps in early detection.

The US is close to eliminating hepatitis B in children, but chronic adult infection and a shifting vaccine policy threaten that progress.

Changes in PrEP for HIV expand choice and reduce risk as new research continues to look for an elusive cure.

An 18-month Illinois pilot linking prison clinicians to endocrinologists via telehealth achieved a mean HbA1c reduction of 1.6 percentage points across 115 incarcerated men with diabetes.

Peter Hotez, MD, discusses which patients may benefit most from newly approved oral COVID-19 postexposure prophylaxis.

Patients with narcolepsy type 1 reported high disease burden, including chronic symptoms like hallucinations, sleep paralysis, and difficulty concentrating.

A pooled nonrandomized trial of AAVrh.10hFXN across 17 patients showed reduced LVMI and lower high-sensitivity troponin I levels at all 3 dose cohorts.

Late-breaking abstracts presented during the Sleep 2026 Annual Meeting provided new data on how the time of year could change sleep duration and the efficacy of low-sodium oxybate.

Cardinal Health hires ex-FCS leader Nathan Walcker to drive The Specialty Alliance's growth, including managed services in gastroenterology and urology.

Tarik Asselah, MD, PhD, explains why HDV RNA suppression deepened through 2 years with tobevibart plus elebsiran.

This new analysis offers some of the most rigorous real-world data to guide treatment decisions for TP53 wild-type chronic lymphocytic leukemia.

The FDA's first new sunscreen ingredient approved in nearly 3 decades is set to reshape the US market. Here is what dermatologists need to know.

Perry Halkitis, PhD, MS, MPH, draws on decades of epidemic response to argue for evidence-based policy, public trust, and equitable care delivery.

The American Heart Association’s Life’s Essential 8 indicates that the key to a healthy heart is through the treatment of sleep, including in obstructive sleep apnea (OSA) and narcolepsy.

FDA approved Rextovy, a 4-mg OTC naloxone nasal spray, expanding access to opioid overdose reversal medications nationwide.

Pooled TETON trial data showed inhaled treprostinil preserved lung function in IPF, supporting an FDA submission planned for 2026.

A new tudy finds 2024-2025 COVID-19 vaccines reduced hospitalization and critical illness risk among adults, although protection waned over time.